|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||1.0400 - 1.0885|
|52-week range||1.0400 - 7.0800|
|Beta (5Y monthly)||1.76|
|PE ratio (TTM)||N/A|
|Earnings date||07 Aug 2023 - 11 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for infringing patents related to cancer detection. The jury agreed with Natera that biotech company ArcherDX Inc's blood-based DNA tests for detecting and monitoring cancer infringed three of its patents. The award was just over half of the $38 million Natera had requested, according to court documents.
Cathie Wood as an investor reminds me of the protagonists in the tornado-chasing classic Twister. The co-founder, CEO, and main stock picker of Ark Invest was active in the market windstorm on Wednesday, and thankfully for us, she posts her daily transactions at the end of every trading day. Wood added to her positions in Twilio (NYSE: TWLO), Palantir (NYSE: PLTR), and Invitae (NYSE: NVTA) on Wednesday.
Joining us today are president and CEO, Ken Knight; our CFO, Roxi Wen and our chief science officer, Dr. Robert Daber. Before we begin, I'd like to remind you that various remarks that we make on this call that are not historical includes those about our vision and business model, the company's strategic business realignment, future financial and operating results; expectations of future growth and reduction in burn rates, and future products, services of our product pipeline and the timing.
Invitae (NVTA) delivered earnings and revenue surprises of 9.76% and 1.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Shares of Invitae Corporation (NYSE: NVTA) closed 11.57% higher on Friday after Cathie Wood, the CEO of Ark Invest, said the stock was undervalued. Wood's Ark Innovation ETF owns more than 18 million shares of Invitae, worth roughly $24 million as of Friday, so her company has a huge stake in the stock, which has declined more than 74% over the past year and more than 27% so far this year. Invitae specializes in genetic testing to improve healthcare outcomes.
Joining us today are president and CEO, Ken Knight; and our CFO, Roxi Wen. Before we begin, I'd like to remind you that various remarks that we make on this call that are not historical including those about our vision and business model, the company's strategic business realignment, future financial and operating results; expectations of future growth and reduction in burn rates, expectations regarding the exchange and equitization of existing notes and extension of debt maturity and future products, services and our product pipeline and the timing.
Invitae (NVTA) delivered earnings and revenue surprises of 38.18% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
With shares down by 91% in the last three years, and 78% in the last 12 months alone, Invitae (NYSE: NVTA) and its investors are bound to be feeling the burn. The genetic testing company's downward spiral led Wall Street analysts to downgrade the stock, and many are suggesting that shareholders quit their positions. Let's explore how realistic it is for Invitae to make a comeback so that you'll know whether the odds are in your favor.
Genetic testing company Invitae (NYSE: NVTA) has a lot of long-term potential as it could help improve the quality of healthcare for people and play a big role in transforming the industry. Below, I'll look at how much a $10,000 investment in the company would be worth today, and whether you should consider buying shares today. In 2018, Invitae was coming off a year where its revenue totaled $68 million and had more than doubled the prior-year's tally of $25 million.
Invitae (NYSE: NVTA) is a promising business specializing in genetic testing, which could be the wave of the future in healthcare. Genetic tests can uncover mutations or variants in your DNA, which can help prevent illnesses and treat them more effectively. Invitae, for instance, has been incurring significant losses and is a bit of a risky company to invest in.
Shares of genetic testing company Invitae (NYSE: NVTA) have surged more than 40% over the past month, a combination of improving investor sentiment toward growth stocks as well as the company's preliminary release of financial results for 2022. Investors need to know about this upcoming event and consider the potential ramifications before buying shares. Earlier this past summer, Invitae's management announced plans to exit non-core businesses to push the company toward positive cash flow.
Three stocks that fit that criteria and while still generating positive growth numbers include Invitae (NYSE: NVTA), Salesforce (NYSE: CRM), and Tesla (NASDAQ: TSLA). Should you buy these three growth stocks right now, or are tougher times ahead for their businesses? Diagnostics company Invitae has plenty of long-term promise.
The bears have prevailed with Invitae this year. But could the future be better for the beaten-down stock?
Vertex Pharmaceuticals (NASDAQ: VRTX) and Invitae (NYSE: NVTA) have gone in different directions this year when it comes to share price, with Vertex's stock up more than 43% so far and Invitae's shares plunging over 84%. Looking at these two biotech stocks from a long-term perspective, is Invitae now the better buy? Or is Vertex's strong run this year likely to extend into 2023?
Invitae (NYSE: NVTA) is a genetic testing company that's in its early growth stages, so shareholders should expect to take on some risk with a stock like this. Or could it be a good long-term investment for growth investors to buy and hold? A big problem with Invitae is that it is burning through lots of cash.
Shares of medical genetics testing company Invitae (NYSE: NVTA) rose 11% on Tuesday. Invitate didn't have any announcements on Tuesday, though it is presenting research this week in Nashville, Tennessee, at the National Society of Genetic Counselors conference. Invitae reported revenue of $133.5 million, up 16.7%, year over year.
Two stocks that could climb fivefold if they make progress toward their goals are Teladoc Health (NYSE: TDOC) and Invitae (NYSE: NVTA). Teladoc and Invitae shares both have lost more than 70% this year. Teladoc disappointed investors with two massive noncash goodwill impairment charges linked to an acquisition.
Invitae (NYSE: NVTA) stock was absolutely crushing it on Wednesday, with its shares skyrocketing 19.4% higher as of 11:11 a.m. ET. The huge gain came after the medical genetics company announced its third-quarter results following the market close on Tuesday. Invitae posted a net loss of $301.2 million, or $1.27 per share, based on generally accepted accounting principles (GAAP).
Hello, everyone, and thank you for joining the Invitae's third quarter 2022 financial results conference call. Joining us today are president and CEO, Ken Knight; and our CFO, Roxi Wen. Before we begin, I'd like to remind you the various remarks that we make on this call that are not historical, including those about our vision and business model, the company's strategic business realignment, future financial and operating results, expectations of future growth and reduction in burn rate and future products, services, our product pipeline, and the timing constitute forward-looking statements within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act.
Invitae (NVTA) delivered earnings and revenue surprises of 28.81% and 0.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
There's significant growth potential in the genetic testing market, but is Invitae in a good position to take advantage of it?
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 8.20% and 14.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Even though the genetics testing specialist didn't divulge the financial details of a new partnership, investors nevertheless were happpy about the news.
Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, it's burned through cash -- and left investors wondering when and if the company can make it to profitability.
Broad market movements, unprofitability, and high short interest seem to be hitting Invitae stock this week.